Neuren Pharmaceuticals Limited (NURPF) Stock Price & Analysis
Neuren Pharmaceuticals Limited (NURPF) — price $13.76 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.74B.
Educational signal · not a buy or sell recommendation · How to read this
Neuren Pharmaceuticals Limited · NURPF
Neuren Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing novel treatments for neurological disorders.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $13.76 | |
| Change on the day | 0.00% | |
| 52-week range | $7.70 – $17.25 | |
| Market capitalisation | $1.74B | |
| Price / earnings (trailing) | 139.67 | |
| Shares traded on the day | 6.2K |
Price & events
Other perspectives
Council score for Neuren Pharmaceuticals (NURPF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Neuren Pharmaceuticals (NURPF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Neuren Pharmaceuticals Limited (NURPF) is the company analyzed here. It employs 8 people and is led by Jonathan Charles Pilcher. In Q2 FY2026 it reported revenue of A$33M and net income of A$5M. The market values it at $1.74B.
What do the latest results show for Neuren Pharmaceuticals (NURPF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of A$33M. Against analyst estimates the company has EPS beat 2 of the last 7 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | A$33M | A$5M | A$0.04 (diluted) |
| Q4 FY2025 | A$36M | A$15M | A$0.12 (diluted) |
| Q2 FY2025 | A$28M | A$15M | A$0.12 (diluted) |
| Q4 FY2024 | A$193M | A$134M | A$1.03 (diluted) |
What are the financial strengths and risks for Neuren Pharmaceuticals (NURPF)?
Short answer · as of
The distress and quality screens read Piotroski F 6. Trailing ratios: ROE 6.0% · ROA 5.9% · current ratio 46.45 · earnings yield 0.7% · free-cash-flow yield 0.2%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NURPF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NURPF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Neuren Pharmaceuticals (NURPF)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
Is NURPF a good stock to buy?
Stock Expert AI does not rate NURPF buy, sell or hold. Neuren Pharmaceuticals Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NURPF stock price today?
The last price recorded for Neuren Pharmaceuticals Limited (NURPF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for NURPF?
Evaluate NURPF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does NURPF data refresh on this page?
NURPF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NURPF's recent stock price performance?
Neuren Pharmaceuticals Limited (NURPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Advanced clinical pipeline with lead candidate trofinetide in Phase III for Rett syndrome, a significant milestone. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NURPF overvalued or undervalued right now?
The trailing P/E of Neuren Pharmaceuticals Limited (NURPF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NURPF before investing?
Before investing in Neuren Pharmaceuticals Limited (NURPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding NURPF to a portfolio?
Key strength of Neuren Pharmaceuticals Limited (NURPF): Advanced clinical pipeline with lead candidate trofinetide in Phase III for Rett syndrome, a significant milestone. Weigh rewards against risks and diversify. Not financial advice.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com